ARTICLE SUMMARY:
As healthcare systems nationwide grapple with the adoption of artificial intelligence and the onslaught of vendors eager to sell AI solutions into their systems, Johns Hopkins Medicine is taking a leading role in building a robust governance platform for vetting AI platforms. Dr. T.Y. Alvin Liu explains.
C-suite leaders of healthcare systems, already under immense pressures on many fronts, are inundated with sales pitches and research proposals for applying artificial intelligence (AI) to solve problems. They are struggling to evaluate their options in a field that is already transforming their organizations and clinical care.
Many healthcare systems don’t have the near-term bandwidth to handle AI, but they need to take advantage of this revolution, says T.Y. Alvin Liu, MD, a vitreoretinal surgeon, who is an endowed professor and the inaugural director of the James P. Gills Jr., MD, and Heather Gills Artificial Intelligence Innovation Center at Johns Hopkins Medicine (JHM) in Baltimore. Liu’s research and experience in scaling AI for clinical and operational purposes within Johns Hopkins is informing the healthcare system’s strategy as it establishes its first governance structure for developing best practices in AI.
Liu is a co-chair (imaging committee) of JHM’s AI and Data Trust Council and serves on the healthcare system’s AI Oversight Team, which was formed in 2024. Beyond his work at JHM, Liu is among a group of clinical leaders and executives in the US pushing to create templates for AI adoption in the nation’s 5,000-plus hospitals, many of which do not have the resources or expertise to evaluate these platforms effectively on their own.
JHM, for example, recently established a formal process for evaluating AI vendors.
